07:51 AM EDT, 03/12/2026 (MT Newswires) -- HLS Therapeutics ( HLTRF ) Thursday reported a narrower fourth-quarter loss.

Net loss was US$1.3 million, or $0.04 per share, compared with a net loss of $3.0 million, or $0.10 per share, in the previous corresponding quarter. Analysts polled by FactSet had expected a loss of US$0.03 per share.

The narrower net loss was due to strong operational discipline and cost optimization initiatives, the company said in a statement.

Revenue decreased 2% to US$15.2 million, primarily due to softer revenue in the U.S. business, but was slightly above the US$15.1 million forecast.

For 2026, HLS is guiding to consolidated revenue of US$56 million to US$60 million, representing mid-single-digit percentage growth.